|
注册号: Registration number: |
ChiCTR2400091843 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-05 09:38:38 |
|
注册时间: Date of Registration: |
2024-11-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
无抽搐电休克及磁休克治疗改善自杀意念及行为的比较疗效研究 |
|
Public title: |
A comparative efficacy study of convulsion-free electroconvulsive shock and magnetic shock therapy to improve suicidal ideation and behavior |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
无抽搐电休克及磁休克治疗改善自杀意念及行为的比较疗效研究 |
|
Scientific title: |
A comparative efficacy study of convulsion-free electroconvulsive shock and magnetic shock therapy to improve suicidal ideation and behavior |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王冉 |
研究负责人: |
王冉 |
|
Applicant: |
Wang Ran |
Study leader: |
Wang Ran |
|
申请注册联系人电话: Applicant telephone: |
+86 15633834532 |
研究负责人电话:
Study leader's |
+86 15633834532 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wr104@hebmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
wangran104@hptmail.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河北医科大学第一医院 |
研究负责人通讯地址: |
河北省石家庄市东岗路89号 |
|
Applicant address: |
The First Hospital of Hebei Medical University |
Study leader's address: |
No. 89, Donggang Road, Shijiazhuang, Hebei |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
河北医科大学第一医院 |
||
|
Applicant's institution: |
The First Hospital of Hebei Medical University |
||
|
研究负责人所在单位: |
河北医科大学第一医院 |
||
|
Affiliation of the Leader: |
the first hospital of hebei medical university |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
【2024】研审第(147)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
河北医科大学第一医院临床研究伦理委员会 |
||
|
Name of the ethic committee: |
Clinical Research Ethics Committee of the First Hospital of Hebei Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-10-16 00:00:00 | ||
|
伦理委员会联系人: |
户培华 |
||
|
Contact Name of the ethic committee: |
Hu PeiHua |
||
|
伦理委员会联系地址: |
河北省石家庄市东岗路89号 |
||
|
Contact Address of the ethic committee: |
No. 89, Donggang Road, Shijiazhuang, Hebei |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 311 87156182 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
18631123450@163.com |
|
研究实施负责(组长)单位: |
河北医科大学第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
the first hospital of hebei medical university |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河北省石家庄市东岗路89号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 89, Donggang Road, Shijiazhuang, Hebei |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自选课题(自筹) |
||||||||||||||||||||||
|
Source(s) of funding: |
Optional project(self-financing) |
||||||||||||||||||||||
|
研究疾病: |
MDD伴自杀 |
||||||||||||||||||||||
|
Target disease: |
MDD with suicide |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本研究为临床观察性研究,选取接受无抽搐电休克治疗的患者及磁休克治疗的MDD伴自杀观念的患者进行临床观察,比较两者在改善自杀意念及行为的疗效。 |
||||||||||||||||||||||
|
Objectives of Study: |
This is a clinical observational study in which patients receiving convulsion-free electroconvulsive therapy and magnetic shock-treated MDD with suicidal ideation were selected for clinical observation to compare the efficacy of both in improving suicidal ideation and behavior. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.经SCID-5-CV访谈存在其他任何精神障碍; 2.有严重躯体疾病史,包括心血管疾病、神经系统疾病,外伤导致的脑损伤; 3.有癫痫病史; 4.不能配合完成量表测评; 5.基础资料、各项评分量表数据缺失或不完善。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. The presence of any other mental disorder as interviewed by the SCID-5-CV; 2. A history of serious physical illness, including cardiovascular and neurologic diseases, and traumatic brain injury; 3. A history of epilepsy; 4. An inability to cooperate in completing the scales; 5.Missing or imperfect data on the baseline information, and on each of the rating scales. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-08-01 00:00:00至 To 2025-08-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-11-15 00:00:00 至 To 2025-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
无 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
None |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |